BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced receipt of a $3.5 million milestone payment under the terms of its Elestrin™ (estradiol gel) licensing agreement with Bradley Pharmaceuticals, Inc. (NYSE: BDY). The payment is the second of two triggered by the December 2006 U.S.

Stock Market Alerts' performance stock list includes: ALL Fuels & Energy Company (OTCBB: AFSE), American Oriental Bioengineering, Inc. (NYSE: AOB), Under Armour, Inc. (NYSE: UA), Bradley Pharmaceuticals, Inc. (NYSE: BDY).

FAIRFIELD, N.J., Sept. 28 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc.

NEW YORK, June 20 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today introduced Elestrin(TM) (estradiol gel 0.06%) to the national media.

BioSante Pharmaceuticals, Inc. (AMEX: BPA) today announced the launch of Elestrin (estradiol gel 0.06%) by the Kenwood Therapeutics Division of Bradley Pharmaceuticals, Inc. (NYSE: BDY). Elestrin is an effective, ultra-low dose transdermal estrogen therapy that was approved by the U.S.